GLOBAL INJECTABLE DRUG DELIVERY MARKET 2019-2028

MARKET OUTLOOK
Triton Market Research's report on the injectable drug delivery market in North America estimates it to grow at a CAGR of 8.26% during the forecast period. The United States and Canada together constitute the market in this region.
The rising prevalence of cancer in the country is primarily driving Canada's injectable drug delivery market. The Canadian Cancer Society states that, nearly 202,400 new cases of cancers were diagnosed in the country in 2016. It is predicted that, 2 out of every 5 Canadians would be diagnosed with cancer in their lifetime, and 1 in 4 persons in the country will lose their life to the disease.
Nanoparticle-based drug delivery systems are being looked upon as a promising solution for cancer treatment. These nanoparticles are the key elements of nanomedicines. In 2016, the Canada Foundation for Innovation revealed that, its University of Toronto Lab successfully created large, orally absorbable molecules from peptides for the treatment of IBD. It is also in the process of developing orally bioavailable solutions to eradicate cancer. Therefore, the steady rise in the cases of cancer, along with the need for effective treatment, is boosting the demand for effective drug delivery systems in Canada, which is directly influencing the growth of the Canadian market over the forecast period.
COMPETITIVE OUTLOOK
Some of the eminent names in this market are Novo Nordisk A/S, Becton Dickinson and Company (BD), Baxter International Inc, Eli Lilly and Company, Elcam Medical, Teva Pharmaceuticals, Schott AG, and Ypsomed Holding AG.

TABLE OF CONTENTS
1. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. PORTER'S FIVE FORCES MODEL
2.2.1. THREAT OF NEW ENTRANT
2.2.2. THREAT OF SUBSTITUTE
2.2.3. BARGAINING POWER OF BUYERS
2.2.4. BARGAINING POWER OF SUPPLIERS
2.2.5. INTENSITY OF COMPETITIVE RIVALRY
2.3. KEY INSIGHT
2.4. KEY BUYING CRITERIA
2.5. REGULATORY FRAMEWORK
2.6. MARKET ATTRACTIVENESS INDEX
2.7. MARKET DRIVERS
2.7.1. INCREASING GERIATRIC POPULATION
2.7.2. TECHNOLOGICAL ADVANCEMENT
2.7.3. GROWING OCCURRENCE OF AUTOIMMUNE DISEASES
2.8. MARKET RESTRAINTS
2.8.1. HIGH MANUFACTURING COST OF INJECTABLE DRUG DELIVERY SYSTEMS
2.9. MARKET OPPORTUNITIES
2.9.1. DEVELOPMENT OF BETTER INJECTABLE SYSTEMS
2.9.2. INCREASE IN HEALTHCARE EXPENDITURE
2.10. MARKET CHALLENGES
2.10.1. DEVELOPMENTS IN ALTERNATE DRUG DELIVERY SYSTEMS
2.10.2. STRINGENT REGULATIONS
3. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY DEVICE TYPE
3.1. PEN INJECTOR
3.2. AUTO?INJECTOR
3.3. NEEDLE-FREE INJECTOR
3.4. PREFILLED SYRINGE
4. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY ROUTE OF ADMINISTRATION
4.1. SUBCUTANEOUS
4.2. INTRAMUSCULAR
4.3. INTRAVENOUS (IV)
4.4. OTHER ROUTE OF ADMINISTRATION
5. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY END-USER
5.1. CLINICS/ PHYSICIAN OFFICES
5.2. AMBULATORY CARE
5.3. HOSPITAL
5.4. HOME-BASED
5.5. OTHER END-USERS
6. INJECTABLE DRUG DELIVERY MARKET – NORTH AMERICA
6.1. COUNTRY ANALYSIS
6.1.1. THE UNITED STATES
6.1.2. CANADA
7. COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC
7.2. BECTON DICKINSON AND COMPANY (BD)
7.3. ELCAM MEDICAL
7.4. ELI LILLY AND COMPANY
7.5. GERRESHEIMER
7.6. INJEX
7.7. NOVARTIS AG
7.8. NOVO NORDISK A/S
7.9. PFIZER INC
7.10. SANOFI SA
7.11. SCHOTT AG
7.12. TERUMO CORPORATION
7.13. TEVA PHARMACEUTICALS
7.14. WEST PHARMACEUTICALS
7.15. YPSOMED HOLDING AG
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.1.1. OBJECTIVES OF STUDY
8.1.2. SCOPE OF STUDY
8.2. SOURCES OF DATA
8.2.1. PRIMARY DATA SOURCES
8.2.2. SECONDARY DATA SOURCES
8.3. RESEARCH METHODOLOGY
8.3.1. EVALUATION OF PROPOSED MARKET
8.3.2. IDENTIFICATION OF DATA SOURCES
8.3.3. ASSESSMENT OF MARKET DETERMINANTS
8.3.4. DATA COLLECTION
8.3.5. DATA VALIDATION & ANALYSIS


LIST OF TABLES
TABLE 1 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)
TABLE 2 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 3 DIFFERENT TYPES OF INSULIN PEN INJECTORS
TABLE 4 MARKETED NEEDLE-FREE INJECTORS PRODUCTS
TABLE 5 LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE
TABLE 6 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 7 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 8 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)

LIST OF FIGURES
FIGURE 1 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 2 KEY BUYING IMPACT ANALYSIS
FIGURE 3 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PEN INJECTOR, 2019-2028 ($ MILLION)
FIGURE 4 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY AUTO?INJECTOR, 2019-2028 ($ MILLION)
FIGURE 5 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)
FIGURE 6 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PREFILLED, 2019-2028 ($ MILLION)
FIGURE 7 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY SUBCUTANEOUS, 2019-2028 ($ MILLION)
FIGURE 8 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY INTRAMUSCULAR , 2019-2028 ($ MILLION)
FIGURE 9 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY INTRAVENOUS , 2019-2028 ($ MILLION)
FIGURE 10 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY OTHER ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
FIGURE 11 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/PHYSICIAN OFFICES, 2019-2028 ($ MILLION)
FIGURE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE, 2019-2028 ($ MILLION)
FIGURE 13 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL, 2019-2028 ($ MILLION)
FIGURE 14 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY HOME-BASED, 2019-2028 ($ MILLION)
FIGURE 15 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY OTHER END-USER, 2019-2028 ($ MILLION)
FIGURE 16 THE UNITED STATES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 17 CANADA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)